Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5K12HL137943-03 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | NIH |
Not provided
Not provided
Not provided
Not provided
Children are often reported to have antibiotics allergies, with approximately 10% of the US population labeled as allergic to an antibiotic. Recent studies have demonstrated that a large majority of children with a penicillin allergy label do not have a true IgE-mediated allergy. Appropriately delabeling antibiotic allergies has been shown to improve patient care outcomes and lower health care costs. However, efforts to implement these assessments in practice are lacking, particularly in the hospital setting. Therefore, there is a need for hospital-based risk assessment and delabeling strategies for hospitalized children. The investigator's objective is to determine the feasibility of implementing a hospital-based approach to penicillin allergy risk stratification and evaluation of patients at low-risk for true allergy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Penicillin Allergy Risk Stratification and Evaluation | This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Penicillin Allergy Risk Stratification and Evaluation | Other | This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of Intervention Measure | Qualitative survey to assess feasibility of intervention | Within 2 weeks of hospital discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Acceptability of Intervention Measure | Qualitative survey to assess acceptability of intervention | Within 2 weeks of hospital discharge |
| Intervention Appropriateness Measure | Qualitative survey to assess appropriateness of intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals admitted to Vanderbilt children's hospital admitted to a Pediatric Hospital Medicine service with a penicillin allergy reported in their chart who are medically stable
Not provided
| Name | Affiliation | Role |
|---|---|---|
| James Antoon, MD, PhD | Vanderbilt University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35678128 | Derived | Antoon JW, Grijalva CG, Grisso AG, Stone CA, Johnson J, Stassun J, Norton AE, Kripalani S, Williams DJ. Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program. Hosp Pediatr. 2022 Jul 1;12(7):e230-e237. doi: 10.1542/hpeds.2021-006369. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Within 2 weeks of hospital discharge |